Technology Platform
Our integrated technology platforms combine advanced science with GMP manufacturing to accelerate breakthroughs in cell and gene therapy. Covering nucleic acids, viral vectors, stem cells, immune cells, gene editing, and antigen development, these platforms ensure both innovation and reliability in every stage of product development.
Our immune cell manufacturing platform is designed to translate cutting-edge immunotherapy research into clinical solutions, enabling the large-scale production of high-quality, clinically compliant immune cell products. With advanced technology concepts, a comprehensive manufacturing system, and rigorous quality control, we are driving the global application of immune cell therapies.
Our stem cell manufacturing platform, built with advanced Ukrainian technology and years of in-house expertise, enables high-quality, GMP-compliant stem cell production for clinical and research applications.
The platform integrates advanced isolation, expansion, formulation, cryopreservation, and storage systems, ensuring product safety, efficacy, and consistency for regenerative medicine and cell therapy.
Our virus production platform is built to meet the growing demand for safe, high-quality, and scalable viral vectors in cell and gene therapy. Covering lentivirus, retrovirus, AAV, adenovirus, and oncolytic virus production, the platform combines optimized upstream processes with advanced purification technologies to deliver clinical-grade products.
Our nucleic acid industrialization platform provides high-quality plasmids and mRNA for cell therapy, gene therapy, and vaccine applications. Combining advanced technology, stringent GMP compliance, and large-scale manufacturing capabilities, we deliver reliable nucleic acid raw materials to accelerate research, clinical translation, and commercialization.
.png)
Our CRISPR-Cas9 gene editing platform is a core driver of innovation in immune cell research and therapy, enabling precise, efficient, and safe genetic modifications. With pioneering achievements such as PD-1 knockout CAR-T cells and universal CAR-T development, we are among the first globally to bring these advanced therapies into clinical trials, generating valuable data that supports their efficacy and safety in solid tumor treatment.
Our recombinant antigen production platform provides high-quality antigens to support immune cell research, diagnostics, and therapeutic development. Utilizing multiple expression systems, including E. coli, yeast, insect cells, and HEK293 human cells. We produce recombinant proteins with precise structural characteristics and strong immunogenicity for advanced research and clinical applications.